Alvotech (ALVO) Stock Rises On Guidance Resolve Despite Lingering Loss Risk

Alvotech shares jumped 7% to US$4.27 today, yet the real story sits in the tug of war between sentiment and the income statement. The stock came into this print already on a strong short term run, with double digit gains over the past month, so expectations were not low.

The headline is simple. A biosimilar specialist that remains loss making just reaffirmed full year revenue guidance of US$650m to US$700m and adjusted earnings before interest, tax, depreciation and amortization of US$180m to US$220m, despite a sharp year on year dip in first half revenue tied to manufacturing remediation.

Is Alvotech’s low 2.7x P/S a genuine mispricing, or is the market pricing in balance sheet and volatility risk? Compare that gap against sector peers in the detailed valuation analysis for Alvotech

Q2 2026 Earnings Summary

• Total Revenue (TTM to Q1 2026 vs. TTM to Q4 2024): US$562.0m vs. US$491.98m (up about 14%)
• Net Income from Continuing Operations (TTM to Q1 2026 vs. TTM to Q4 2024): loss of US$80.73m vs. loss of US$231.86m (loss narrowed by about 65%)
• Basic EPS (TTM to Q1 2026 vs. TTM to Q4 2024): loss of US$0.28 per share vs. loss of US$0.87 per share (per share loss reduced by about 68%)
• Product Pipeline Activity (Latest Quarter vs. Prior Year Quarter): 2 products approved and 2 launched in Q4 2025 vs. 2 products approved and 1 launched in Q4 2024 (higher launch activity across the biosimilar portfolio)

If you prefer clean visuals instead of another wall of earnings tables and guidance figures, you can see Alvotech’s full financial picture, including how the balance sheet compares with its revenue ambitions, in the interactive company report for Alvotech.

Alvotech Bull Case Hangs On Execution Milestones Hit

The bullish story on Alvotech is that a broad biosimilar portfolio, cleaner FDA footing and emerging operating leverage can turn today’s investment phase into a stronger cash engine. Recent results give that view some concrete milestones. Management reaffirmed 2026 revenue and adjusted EBITDA guidance despite H1 revenue of US$212m and a decline of 31% year on year. That signals confidence in the launch and milestone pipeline rather than a reset.

Regulatory progress is a clear proof point. The Reykjavik plant inspection closed with a VAI outcome and the site remains FDA approved. Multiple BLAs were resubmitted in June with 6 month review clocks, and AVT16 for Entyvio is now under FDA review with Teva lined up for commercialization. Financing also lines up with the growth plan. Around US$240m of new capital extends the runway for these launches, even if it comes with higher leverage.

Track how this launch heavy, guidance reaffirming Alvotech story lines up with institutional expectations by checking whether analysts see more upside ahead or think the market is getting ahead of itself with the consensus price target analysis for Alvotech.

Alvotech Bears Focus On Execution Slippage, Not Guidance

The bearish view on Alvotech is that regulatory and partner risk, thin product margins and leverage make guidance fragile. H1 results give that view some support. Revenue of US$212m fell 31% year on year and product margin sat at about 6% to 8% despite gross margin near 54%. That shows the vertically integrated model is not yet translating into strong product level economics.

Bears also flag reliance on milestone and partner flows. Management explicitly links a “strong Q4” and reaffirmed US$650m to US$700m revenue and US$180m to US$220m adjusted EBITDA to concentrated milestone and licensing income and to partner ordering patterns. That is execution risk, not yet a miss, but slippage here would hit both cash and earnings. On the positive side, the Reykjavik inspection closing as VAI and BLAs back under review reduce the harshest regulatory scenario that assumed prolonged FDA roadblocks.

After a revenue profile that leans heavily on milestones and a balance sheet carrying negative equity, it is fair to ask whether these are isolated issues or early signs of deeper fragility in Alvotech. Review the independent risk scoring and expose any additional structural warning signs in our risk analysis for Alvotech which shows 2 important warning signs.

Stay Ahead Of Your Next Move

If the mix of reaffirmed guidance, regulatory milestones and execution risk around Alvotech has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch how sentiment reacts to each earnings and FDA update. Once you decide to take a position, use the Portfolio Command Center to cut through market noise and focus on the key developments that matter for your holdings. For a longer term view, tap into the collective insight of thousands of investors through the Community and see how others are interpreting the same data. By surfacing potential catalysts and risks early, you give yourself the opportunity to stay ahead of the market and make decisions with confidence.

Seeking Fresh Alternatives Beyond Alvotech?

Some of the sharpest breakouts and cleanest momentum often start flying under the radar for now. Scan these fresh ideas before the crowd catches up and consider them for your watchlist.

• Spot companies with growing cash strength and limited balance sheet stress, then compare them side by side using the curated list of solid balance sheet and fundamentals stocks (50 results).
• Explore potential secular shifts in digital assets by screening companies linked to blockchain infrastructure and crypto adoption through our focused 20 cryptocurrency and blockchain stocks.
• Look for stocks where cash generation and dividend trends may support high yields by scanning our curated set of 12 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com